COMPANY PROFILE

MARAbio

Precision immunology firm advancing early autism detection with 90% predictive accuracy through maternal antibody blood tests

Salt Lake City, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About MARAbio

MARAbio Systems, Inc. is a precision immunology company focused on the early detection and mitigation of Maternal Autoantibody Related Autism (MARA). Utilizing a proprietary blood test, MARAbio identifies a specific cluster of antibodies in women either prior to pregnancy or as early as birth, which are linked to MARA. This test offers over 90% predictive accuracy for diagnosing severe autism in children before clinical symptoms appear. The company operates in the healthcare and diagnostics market, primarily serving expectant mothers and healthcare providers. MARAbio's business model revolves around offering its exclusive testing services, which are based on key discoveries by Dr. Judy Van de Water at the UC Davis MIND Institute. Revenue is generated through the sale of these diagnostic tests, which enable early intervention and tailored therapeutic approaches, potentially improving outcomes for children with autism. The company's vision is to prevent the most severe effects of autism by facilitating early diagnosis and intervention.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Salt Lake City, United States
Employees: 21
Open positions: None listed
Dealroom signal: 55.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Health and Wellness, Autism, Health Diagnostics, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2024	$19M	$76M	MAK Capital	↗
OtherOther financing	Jan 2019	$0	—	Autism Impact Fund	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

MARAbio website traffic

Latest recorded traffic for MARAbio is 4K monthly website visits, up 73.9% over the last three months. MARAbio's team grew 23.5% over the past year.

Latest monthly visits4K 3-month web change+73.9% 1-year team growth+23.5%

Monthly website visitsJan 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBiotomeDeveloping high-precision antibody diagnostics	City of Nedlands, Australia	Operational	10	$1.1M	$8.4M
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational
EOEpi OneDeveloping a groundbreaking cancer diagnosis platform for early detection, prognosis, and post-diagnosis drug response prediction	New York City, United States	Operational
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
RORadionetics OncologyRadionetics Oncology is a precision oncology company focusing on the discovery and development of radiopharmaceuticals	San Diego, United States	Operational
ASAtley SolutionsAutomated, standardised and reproducible production of At-211 radiopharmaceuticals for targeted alpha therapy	Göteborgs Stad, Sweden	Operational
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
OXOXcanAI-powered liquid biopsy tests for early cancer detection	Oxford, United Kingdom	Operational